Rocha, L., Huitron, C., Caceres, J.R., et al. (2004) Interleukin-2 (IL-2) Receptor-βγ Signaling Is Activated by c-Kit in the Absence of IL-2, or By Exogenous IL-2 via JAK3/STAT5 in Human Papillomavirus-Associated Cervical Cancer. Cellular Signalling, 16, 1239-1247.
https://doi.org/10.1016/j.cellsig.2004.03.011

has been cited by the following article:

• TITLE: Clinical Observation of rhIL-2 Combined with Zhenqi Fuzheng and BaofuKang Suppository in the Treatment of Cervical Intraepithelial Neoplasia II with HPV Infection

  AUTHORS: Yu Cai, Jianjun Zhai, Jinping Xun, Xiaojin He

  KEYWORDS: Cervical Intraepithelial Neoplasia II, Human Papilloma Virus, Recombinant Human Interleukin-2, Zhenqi Fuzheng, Baofukang

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.10 No.8, August 14, 2020

  ABSTRACT: Objective: To investigate the clinical effects of recombinant human interleukin-2 (rhIL-2) combined with Zhenqi Fuzheng and Baofukang on cervical intraepithelial neoplasia II (CINII) combined with human papilloma virus infection. Methods: There were 593 patients diagnosed with CINII with HPV infection, including 296 in the control group and 297 in the experimental group. The control group was given only Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine. The experimental group was treated with rhIL-2 injection in addition to Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine which is treated for 3 months. After 3 months, Thinprep cytologic test (TCT), human papilloma virus (HPV) quantitative examination and colposcopy biopsy were reviewed. Results: After 3 months of treatment, the negative conversion rate and total effective rate of HPV in the control group were 58.11% and 70.95% respectively, and the negative conversion rate and total effective rate of the experimental group were 79.46% and 90.57% respectively. There was significant difference between the two groups (p = 0.000). The curative rate of cervical lesions was significantly higher in the test group than in the control group, 89.56%, 68.91%, respectively. The statistical difference between the two groups is significant (p = 0.000). Conclusion: It has an essential clinical value that HPV infection patients and cervical intraepithelial neoplasia II associated with HPV infection patients are treated by rhIL-2 combined with Zhenqifuzheng and Baofukang, which is safe, effective, non-invasive, reusable advantages. However, the long-term efficacy and side effects need to be further studied.